What the UK economy can learn from the pharmaceutical sector

15 June 2020
jameel_zayed

Amid the unfamiliar circumstances of the last few months, much has been made of the rapid innovation that businesses up and down the UK have been forced to undertake, writes Jameel Zayed (pictured), from innovation funding consultancy Leyton, in an Expert View piece.

With millions of people adapting to working from home virtually overnight, businesses have found new ways to adapt to these challenges, potentially changing the way we work forever.

However, whole sectors of the economy have struggled in the new circumstances – retail, hospitality and tourism have been victims of the national lockdown.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical